Vital KSK Holdings, Inc. (TYO:3151)
1,274.00
-8.00 (-0.62%)
Aug 20, 2025, 3:30 PM JST
Vital KSK Holdings Revenue
Vital KSK Holdings had revenue of 148.18B JPY in the quarter ending June 30, 2025, with 1.31% growth. This brings the company's revenue in the last twelve months to 602.28B, up 2.22% year-over-year. In the fiscal year ending March 31, 2025, Vital KSK Holdings had annual revenue of 600.37B with 2.19% growth.
Revenue (ttm)
602.28B
Revenue Growth
+2.22%
P/S Ratio
0.10
Revenue / Employee
160.35M
Employees
3,756
Market Cap
61.50B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 600.37B | 12.89B | 2.19% |
Mar 31, 2024 | 587.48B | 7.71B | 1.33% |
Mar 31, 2023 | 579.77B | 2.52B | 0.44% |
Mar 31, 2022 | 577.25B | 40.22B | 7.49% |
Mar 31, 2021 | 537.03B | -25.48B | -4.53% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,196.22B |
Takeda Pharmaceutical Company | 4,480.25B |
Daiichi Sankyo Company | 1,924.68B |
HOYA Corporation | 876.09B |
Otsuka Holdings | 2,401.70B |
Terumo | 1,037.94B |
Astellas Pharma | 1,944.99B |
Shionogi & | 440.50B |